Patents by Inventor Austin L. Gurney

Austin L. Gurney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating inflammatory disease by inhibition of IL-17 production
    Patent number: 8287869
    Abstract: The invention concerns inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23). The invention further concerns the use of IL-23 antagonists in the treatment of inflammatory diseases characterized by the presence of elevated levels of IL-17. IL-23 antagonists include, without limitation, antibodies specifically binding to a subunit or IL-17 or an IL-17 receptor. The invention additionally concerns induction of IL-7 production by using an IL-23 agonist.
    Type: Grant
    Filed: January 7, 2009
    Date of Patent: October 16, 2012
    Assignee: Genentech, Inc.
    Inventor: Austin L. Gurney
  • TREATMENT OF COMPLEMENT-ASSOCIATED DISORDERS
    Publication number: 20120189626
    Abstract: The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the treatment of complement-associated disorders.
    Type: Application
    Filed: December 15, 2011
    Publication date: July 26, 2012
    Inventors: Avi Ashkenazi, Karim Yussef Helmy, Sherman Fong, Audrey Goddard, Austin L. Gurney, Kenneth James Katschke, JR., Menno Van Lookeren, William I. Wood
  • Antibodies to notch receptors
    Patent number: 8226943
    Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.
    Type: Grant
    Filed: July 8, 2009
    Date of Patent: July 24, 2012
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
  • Antibodies to lymphotoxin-?
    Patent number: 8216807
    Abstract: The invention provides various antibodies that bind to lymphotoxin-?, methods for making such antibodies, compositions and articles incorporating such antibodies, and their uses in treating, for example, an autoimmune disorder. The antibodies include murine, chimeric, and humanized antibodies.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: July 10, 2012
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Jane L. Grogan, Austin L. Gurney, Krista McCutcheon
  • Anti-PRO87299 Antibodies
    Publication number: 20120171208
    Abstract: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related disease.
    Type: Application
    Filed: March 2, 2012
    Publication date: July 5, 2012
    Applicant: Genentech, Inc.
    Inventors: Hilary Clark, Daniel L. Eaton, Bernd Wranik, Wenjun Ouyang, Lino Gonzalez, Austin L. Gurney, Kelly Loyet
  • Methods for up-regulating PAP1 in animals suffering from pancreatic disorders
    Patent number: 8178082
    Abstract: The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: May 15, 2012
    Assignee: Genentech, Inc.
    Inventors: Austin L. Gurney, Sudeepta Aggarwal, Ming-Hong Xie, Ellen M. Maruoka, Jessica S. Foster, Audrey Goddard, William I. Wood
  • Compositions and methods for treating and diagnosing cancer
    Patent number: 8158757
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.
    Type: Grant
    Filed: July 2, 2008
    Date of Patent: April 17, 2012
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Aaron K. Sato
  • IL-17 HOMOLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20120064073
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: October 10, 2011
    Publication date: March 15, 2012
    Inventors: Jian Chen, Ellen Fllvaroff, Sherman Fong, Dorothy French, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hillan, Sarah G. Hymowitz, Hanzhong Li, James Pan, Melissa A. Starovasnik, Daniel Tumas, Menno Van Lookeren, Richard Vandlen, Colin K. Watanabe, P. Mickey Williams, William I. Wood, Daniel G. Yansura
  • IL-17 HOMOLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
    Publication number: 20120058909
    Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.
    Type: Application
    Filed: October 10, 2011
    Publication date: March 8, 2012
    Inventors: Jian Chen, Elleri Filvaroff, Sherman Fong, Dorothy French, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hilian, Sarah G. Hymowitz, Hanzhong Li, James Pan, Melissa A. Starovasnik, Daniel Tumas, Menno Van Lookeren, Richard Vandlen, Colin K. Watanabe, P. Mickey Williams, William I. Wood, Daniel G. Yansura
  • Frizzled-Binding Agents and Uses Thereof
    Publication number: 20120027778
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and other polypeptides, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided. Screening methods are also provided.
    Type: Application
    Filed: April 1, 2011
    Publication date: February 2, 2012
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventor: Austin L. GURNEY
  • PRO1120 polypeptides
    Patent number: 8106156
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: January 31, 2012
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Paul J Godowski, Austin L Gurney, Victoria Smith, William I Wood
  • TAT294 polypeptides
    Patent number: 8097700
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: January 17, 2012
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Dan L. Eaton, Audrey Goddard, Austin L. Gurney, William I. Wood, Thomas D. Wu
  • Treatment of complement-associated disorders
    Patent number: 8088386
    Abstract: The present invention concerns a recently discovered macrophage specific receptor, CRIg, and its use in the treatment of complement-associated disorders.
    Type: Grant
    Filed: June 22, 2005
    Date of Patent: January 3, 2012
    Assignee: Genentech, Inc.
    Inventors: Avi Ashkenazi, Karim Yussef Helmy, Sherman Fong, Audrey Goddard, Austin L. Gurney, Kenneth James Katschke, Jr., Menno Van Lookeren, William I. Wood
  • FRIZZLED-BINDING AGENTS AND USES THEREOF
    Publication number: 20110318341
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.
    Type: Application
    Filed: June 20, 2011
    Publication date: December 29, 2011
    Inventors: Austin L. Gurney, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
  • Compositions and methods for the diagnosis and treatment of tumor
    Patent number: 8084200
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: December 27, 2011
    Assignee: Genentech, Inc.
    Inventors: Avi J. Ashkenazi, Gretchen Frantz, Audrey Goddard, Lino Gonzalez, Austin L. Gurney, Paul Polakis, Andrew Polson, William I. Wood, Thomas D. Wu, Zemin Zhang
  • WISP POLYPEPTIDES AND NUCLEIC ACIDS ENCODING SAME
    Publication number: 20110311540
    Abstract: Wnt-1-Induced Secreted Proteins (WISPs) are provided, whose genes are induced at least by Wnt-1. Also provided are nucleic acid molecules encoding those polypeptides, as well as vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides, and methods for producing the polypeptides.
    Type: Application
    Filed: May 26, 2011
    Publication date: December 22, 2011
    Inventors: David Botstein, Robert L. Cohen, Audrey D. Goddard, Austin L. Gurney, Kenneth J. Hillan, David A. Lawrence, Arnold J. Levine, Diane Pennica, Margaret Ann Roy, William I. Wood
  • NOTCH1 RECEPTOR BINDING AGENTS AND METHODS OF USE THEREOF
    Publication number: 20110311552
    Abstract: Means and methods for the diagnosis, characterization, prognosis and treatment of cancer, specifically targeting cancer stem cells are disclosed Provided is an antibody that specifically binds to a non-ligand binding membrane proximal region of the extracellular domain of a human Notch receptor and inhibits tumor growth, and a method of treating cancer comprising administering said antibody to a subject.
    Type: Application
    Filed: July 8, 2009
    Publication date: December 22, 2011
    Inventors: Austin L. Gurney, Timothy Hoey, Maureen Fitch Bruhns, Fumiko Takada Axelrod
  • Wnt Antagonists and Methods of Treatment and Screening
    Publication number: 20110305695
    Abstract: The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and Ror receptors and their use.
    Type: Application
    Filed: January 12, 2011
    Publication date: December 15, 2011
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Sanjeev H. SATYAL, Satyajit Sujit Kumar Mitra, Austin L. Gurney
  • DDR1-Binding Agents and Methods of Use Thereof
    Publication number: 20110287011
    Abstract: Disclosed are DDR1 binding agents and methods of using the agents for treating diseases such as cancer. The disclosure provides antibodies that specifically bind to an extracellular domain of DDR1 and modulate DDR1 activity. The disclosure further provides methods of using agents that modulate the activity of DDRI, such as antibodies that specifically bind DDR1, to reduce the tumorigenicity of tumors comprising cancer stem cells by reducing the frequency or number of cancer stem cells in the tumor. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: August 12, 2009
    Publication date: November 24, 2011
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Edward Thein Htun Van Der Horst, Sanjeev H. Satyal
  • Methods for Identifying and Isolating Cells Expressing a Polypeptide
    Publication number: 20110287979
    Abstract: The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.
    Type: Application
    Filed: February 11, 2011
    Publication date: November 24, 2011
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Alexandra L. L. Lazetic, Christopher J. Bond